about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Hori­zon touts PhIV win for Te­pez­za; FDA sets ad­comm dates for Sarep­ta, Pfiz­er, Ei­sai apps

3 years ago
News Briefing

Dig­i­tal ther­a­peu­tics mak­er Pear files for bank­rupt­cy, lays off 170 staffers — in­clud­ing CEO

3 years ago
People

Evotec shuts down IT sys­tems in wake of cy­ber­at­tack

3 years ago
Pharma

VC trio de­buts seed fund; Take­da cuts ear­ly gene ther­a­py work; Bio­gen’s new face of BD; Biotech in­vestors get hands ...

3 years ago
Weekly

Ex-Cin­Cor CEO Marc de Garidel lands at Abi­vax af­ter ne­go­ti­at­ing $1.8B cash sale

3 years ago
People

Es­tée Laud­er's fam­i­ly in­jects $200M in­to Alzheimer’s Drug Dis­cov­ery Foun­da­tion

3 years ago
R&D

Fol­low­ing clin­i­cal set­backs, NGM Bio lays off 33% of staffers as founder de­parts

3 years ago
People

Scor­pi­on scores $65M as it lines up a part­ner to take EGFR pro­grams glob­al

3 years ago
Deals

On­coSec re­ports flop for IL-12/Keytru­da com­bo in what may be fi­nal blow

3 years ago
R&D

Biotech launched dur­ing Covid — for Covid — looks for strate­gic al­ter­na­tives af­ter an­tivi­ral fails PhII tri­al

3 years ago
R&D
Coronavirus

Vedere Bio II, gene ther­a­py biotech born out of No­var­tis buy­out, clos­es down

3 years ago
People

Top 15 bio­phar­ma R&D spenders; The re­turn of Big Car­dio; Math­ai Mam­men takes biotech CEO role; Kris­ten Hege’s next ...

3 years ago
Weekly

Jim Mullen scours pri­vate eq­ui­ty deals amid biotech win­ter; Ex-Ab­b­Vie med­ical chief suc­ceeds Brig­gs Mor­ri­son at ...

3 years ago
Peer Review

Gala­pa­gos sends some em­ploy­ees — and a re­search unit — off to drug dis­cov­ery CRO as part of re­org

3 years ago
People
Deals

FDA grants full ap­proval to Keytru­da in tu­mor-ag­nos­tic set­ting; Can­del paus­es tri­al en­roll­ment

3 years ago
News Briefing

FDA lifts par­tial clin­i­cal hold on Vig­il Neu­ro­science's TREM2 an­ti­body, re­mov­ing dos­ing cap

3 years ago
FDA+

GSK picks up Scynex­is' FDA-ap­proved an­ti­fun­gal drug for $90M up­front

3 years ago
Deals
Pharma

Alec­tor cuts 11% of work­force as it dou­bles down on late-stage neu­ro pro­grams part­nered with GSK, Ab­b­Vie

3 years ago
People
R&D

Hear­ing-fo­cused biotech grabs trio of pro­grams from Oton­o­my's fire sale

3 years ago
Deals

FDA lifts par­tial hold on Blue­print­'s CDK2 in­hibitor

3 years ago
FDA+

Bio­mea goes for $125M of­fer­ing af­ter ear­ly di­a­betes da­ta near­ly dou­bled stock price

3 years ago
Financing

Pri­vate eq­ui­ty firm taps ex-Ed­i­tas CEO Jim Mullen to help ex­pand phar­ma port­fo­lio — with a nod to cell, gene ...

3 years ago
People

Gun­ning for 2023 ap­proval, GSK de­tails PhI­II da­ta for Jem­per­li in front­line en­dome­tri­al can­cer

3 years ago
R&D
Pharma

Ab­b­Vie drops Cy­tomX part­ner­ship, leav­ing PhII pro­gram in the air

3 years ago
Deals
First page Previous page 13141516171819 Next page Last page
A service from the Financial Times